230 related articles for article (PubMed ID: 9252680)
41. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
[TBL] [Abstract][Full Text] [Related]
42. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
Wesierska-Gadek J; Kramer MP; Schmid G
J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
[TBL] [Abstract][Full Text] [Related]
43. Ras farnesyltransferase: a new therapeutic target.
Leonard DM
J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
[No Abstract] [Full Text] [Related]
44. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
45. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
46. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
Bishop WR; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
J Biol Chem; 1995 Dec; 270(51):30611-8. PubMed ID: 8530497
[TBL] [Abstract][Full Text] [Related]
47. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell RB; Liu D; Buser CA; Davide JP; DePuy E; Hamilton K; Koblan KS; Lee Y; Mosser S; Motzel SL; Abbruzzese JL; Fuchs CS; Rowinsky EK; Rubin EH; Sharma S; Deutsch PJ; Mazina KE; Morrison BW; Wildonger L; Yao SL; Kohl NE
Mol Cancer Ther; 2002 Jul; 1(9):747-58. PubMed ID: 12479371
[TBL] [Abstract][Full Text] [Related]
48. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
[TBL] [Abstract][Full Text] [Related]
49. Inhibitors of farnesyltransferase and Ras processing peptidase.
Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
[TBL] [Abstract][Full Text] [Related]
50. High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway.
Mather A; Chen XM; McGinn S; Field MJ; Sumual S; Mangiafico S; Zhang Y; Kelly DJ; Pollock CA
Int J Biochem Cell Biol; 2009 Mar; 41(3):561-9. PubMed ID: 18692592
[TBL] [Abstract][Full Text] [Related]
51. High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.
Buser CA; Dinsmore CJ; Fernandes C; Greenberg I; Hamilton K; Mosser SD; Walsh ES; Williams TM; Koblan KS
Anal Biochem; 2001 Mar; 290(1):126-37. PubMed ID: 11180946
[TBL] [Abstract][Full Text] [Related]
52. [Three dimensional quantitative structure-activity relationship of a series of benzocylohepatpyridine farnesyltransferase inhibitors].
Wan SB; Yi X; Guo ZR
Yao Xue Xue Bao; 2002 Apr; 37(4):257-62. PubMed ID: 12579819
[TBL] [Abstract][Full Text] [Related]
53. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells.
Kothapalli R; Guthrie N; Chambers AF; Carroll KK
Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827
[TBL] [Abstract][Full Text] [Related]
54. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.
Leonard DM; Shuler KR; Poulter CJ; Eaton SR; Sawyer TK; Hodges JC; Su TZ; Scholten JD; Gowan RC; Sebolt-Leopold JS; Doherty AM
J Med Chem; 1997 Jan; 40(2):192-200. PubMed ID: 9003517
[TBL] [Abstract][Full Text] [Related]
55. Hydroxamic acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.
Patel DV; Young MG; Robinson SP; Hunihan L; Dean BJ; Gordon EM
J Med Chem; 1996 Oct; 39(21):4197-210. PubMed ID: 8863797
[TBL] [Abstract][Full Text] [Related]
56. Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
[TBL] [Abstract][Full Text] [Related]
57. Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity.
Zhang FL; Fu HW; Casey PJ; Bishop WR
Biochemistry; 1996 Jun; 35(25):8166-71. PubMed ID: 8679569
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells.
Ren Z; Elson CE; Gould MN
Biochem Pharmacol; 1997 Jul; 54(1):113-20. PubMed ID: 9296357
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
[TBL] [Abstract][Full Text] [Related]
60. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
